4-(2-(1,3,4-oxadiazol-2-yl)pyridin-4-yloxy)aniline | 758709-89-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-(1,3,4-oxadiazol-2-yl)pyridin-4-yloxy)aniline
• 英文别名: 4-(2-[1,3,4]Oxadiazol-2-yl-pyridin-4-yloxy)phenylamine；4-[2-(1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxyaniline
• CAS: 758709-89-6
• 化学式: C₁₃H₁₀N₄O₂
• 分子量: 254.248
• InChiKey: JVCRMEFHRPQYHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-(4-氨基苯氧基)-N-甲基-2-吡啶甲酰胺 、 4-氯-2-吡啶甲酸 以 乙酸乙酯 为溶剂， 生成 4-(2-(1,3,4-oxadiazol-2-yl)pyridin-4-yloxy)aniline
  参考文献：
  名称：

  SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS

  摘要：

  本发明涉及新型二芳基脲化合物，含有这些化合物的药物组合物以及将这些化合物或组合物用于治疗增生和血管生成紊乱的方法，作为唯一药物或与细胞毒性治疗联合使用。

  公开号：

  US20100075971A1

文献信息

• NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：Lang Hengyuan

  公开号：US20070155764A1

  公开（公告）日：2007-07-05

  The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.

  本发明涉及化合物和方法，用作蛋白激酶的抑制剂，包括B-Raf以及几种受体酪氨酸激酶和细胞质酪氨酸激酶。本发明涉及新的取代嘧啶氧基脲化合物II、III和IV的配方及其作为药物治疗疾病的应用。还提供了在人类或动物主体中调节蛋白激酶活性的方法，用于治疗癌症等疾病。
• Substituted pyridine derivatives useful in the treatment of cancer and other disorders
  申请人：——

  公开号：US20040229937A1

  公开（公告）日：2004-11-18

  This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

  本发明涉及新型二芳基脲、含有这些化合物的制药组合物以及将这些化合物或组合物用于治疗高增殖和血管生成障碍的用途，作为唯一的药物或与细胞毒性治疗联合使用。
• [EN] SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS<br/>[FR] DERIVES DE PYRIDINE SUBSTITUES UTILISES POUR TRAITER DES CANCERS ET D'AUTRES TROUBLES
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2004078128A2

  公开（公告）日：2004-09-16

  This invention relates to novel diaryl ureas of formula I wherein A is phenyl, naphthyl, mono- or bi-cyclic heteroaryl, or a group of the formula B is phenyl, naphthyl, or pyridyl, L is a bridging group Q is: (1) C(S)NR4R5; (2) C(O)NR7-NR4R5; (3) tetrazolyl; (4) imidazolyl; (5) imidazoline-2-yl; (6) 1,3,4-oxadiazoline-2-yl; (7) 1,3-thiazoline-2-yl; (8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl; (9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or (10) a group of the formula and, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
• [EN] NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES<br/>[FR] UREES PYRIMIDINYLOXY SUBSTITUEES UTILES COMME INHIBITEURS DES PROTEINES KINASES
  申请人：KALYPSYS INC

  公开号：WO2007076473A2

  公开（公告）日：2007-07-05

  [EN] The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.
  [FR] Composés et procédés utiles pour l'inhibition des protéines kinases, y compris les kinases B-Raf et plusieurs tyrosines kinases de type récepteur tyrosine et cytoplasmique. On décrit des composés d'urées pyrimidinyloxy substituées de formules II, III et IV et des compositions, et leur application comme produits pharmaceutiques pour le traitement de maladies. On décrit également des procédés de modulation d'activité de protéine kinase chez un sujet humain ou animal, pour le traitement de maladies comme le cancer.